Trial site
Ottawa Regional Hospital and Healthcare Center
Ottawa, Illinois 61350, United StatesNot linked to an institution yet
- 15running trials
- 12closed trials
The trials here
What the 27 trials at this site are about, from their registry records.
- Phase
- Phase 319 trials
- Phase 28 trials
- Status
- Active, not recruiting15 trials
- Completed12 trials
- Lead sponsor
- National Cancer Institute (NCI)21 trials
- SWOG Cancer Research Network3 trials
- Alliance for Clinical Trials in Oncology1 trial
- ECOG-ACRIN Cancer Research Group1 trial
- ETOP IBCSG Partners Foundation1 trial
Running trials
Active, not recruiting
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
S0820, Adenoma and Second Primary Prevention Trial
NCT01349881· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT01708954· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
NCT01575548· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
NCT01169337· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT01134614· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01081262· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
NCT01142388· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00644228· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00602641· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
NCT00569127· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
NCT00114101· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT00070499· Phase 2· National Cancer Institute (NCI)· Source
Closed trials
Completed
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT01950390· Phase 2· National Cancer Institute (NCI)· Source
Completed
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
NCT01824875· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Completed
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT01708941· Phase 2· National Cancer Institute (NCI)· Source
Completed
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
NCT01809691· Phase 3· SWOG Cancer Research Network· Source
Completed
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
NCT01120249· Phase 3· SWOG Cancer Research Network· Source
Completed
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
NCT01251861· Phase 2· National Cancer Institute (NCI)· Source
Completed
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01167712· Phase 3· National Cancer Institute (NCI)· Source
Completed
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00601900· Phase 3· National Cancer Institute (NCI)· Source
Completed
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT00632853· Phase 3· Alliance for Clinical Trials in Oncology· Source
Completed
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
NCT00324805· Phase 3· National Cancer Institute (NCI)· Source
Completed
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
NCT00217737· Phase 3· National Cancer Institute (NCI)· Source
Completed
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source
Report an error